|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 37.26 USD | -1.45% |
|
-4.87% | -69.32% |
| 10/06 | Sarepta Likely to Meet Revised Guidance, Oppenheimer Says | MT |
| 07/06 | Sarepta Therapeutics Shares Rise After Upgrade From Scotiabank | MT |
| Capitalization | 371.59Cr 323.58Cr 304.6Cr 274.33Cr 507.93Cr 32TCr 570.12Cr 3.55TCr 1.37TCr 15TCr 1.39TCr 1.36TCr 54TCr | P/E ratio 2025 * |
-18.1x | P/E ratio 2026 * | 5.96x |
|---|---|---|---|---|---|
| Enterprise value | 372.17Cr 324.09Cr 305.08Cr 274.77Cr 508.73Cr 32TCr 571.02Cr 3.55TCr 1.38TCr 15TCr 1.4TCr 1.37TCr 54TCr | EV / Sales 2025 * |
1.46x | EV / Sales 2026 * | 0.75x |
| Free-Float |
95.63% | Yield 2025 * |
-
| Yield 2026 * | - |
More valuation ratios
* Estimated data
More news
Last Transcript: Sarepta Therapeutics, Inc.
More recommendations
More press releases
More news
| 1 day | -1.45% | ||
| 1 week | -4.87% | ||
| Current month | -0.80% | ||
| 1 month | +2.56% | ||
| 3 months | -62.61% | ||
| 6 months | -70.03% | ||
| Current year | -69.32% |
| 1 week | 36.8 |  | 43.92 |
| 1 month | 34.1 | | 44.14 |
| Current year | 34.1 | | 129.84 |
| 1 year | 34.1 | | 173.25 |
| 3 years | 34.1 | | 173.25 |
| 5 years | 34.1 | | 181.83 |
| 10 years | 8 | | 181.83 |
| Manager | Title | Age | Since |
|---|---|---|---|
Douglas Ingram
CEO | Chief Executive Officer | 62 | 26/06/2017 |
Ian Estepan
DFI | Director of Finance/CFO | 49 | 14/12/2020 |
Bilal Arif
CTO | Chief Tech/Sci/R&D Officer | 53 | 01/12/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
M. Wilsey
CHM | Chairman | 72 | 16/04/2015 |
| Director/Board Member | 86 | 01/06/2010 | |
Richard Barry
BRD | Director/Board Member | 66 | 02/06/2015 |
| Name | Weight | AuM | 1st Jan change | |
|---|---|---|---|---|
| 4.63% | 1 M€ | -.--% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -1.45% | -4.87% | -68.91% | -44.33% | 371.59Cr | ||
| +4.52% | +5.47% | -12.79% | -18.35% | 354.02Cr | ||
| -0.33% | +1.10% | - | - | 11Cr | ||
| Average | +0.91% | -0.05% | -40.85% | -31.34% | 245.46Cr | |
| Weighted average by Cap. | +1.44% | -1.00% | -41.53% | -31.65% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 255.53Cr 222.52Cr 209.47Cr 188.65Cr 349.29Cr 22TCr 392.06Cr 2.44TCr 945.13Cr 10TCr 958.42Cr 938.51Cr 37TCr | 296.12Cr 257.86Cr 242.74Cr 218.62Cr 404.77Cr 25TCr 454.33Cr 2.83TCr 1.1TCr 12TCr 1.11TCr 1.09TCr 43TCr |
| Net income | -23Cr -20Cr -19Cr -17Cr -32Cr -1.99TCr -36Cr -222.87Cr -86Cr -912.99Cr -88Cr -86Cr -3.38TCr | 77Cr 67Cr 63Cr 57Cr 105.26Cr 6.58TCr 118.15Cr 735.5Cr 284.82Cr 3.01TCr 288.82Cr 282.82Cr 11TCr |
| Net Debt | 58.61L 51.03L 48.04L 43.27L 80.11L 50Cr 89.92L 5.6Cr 2.17Cr 23Cr 2.2Cr 2.15Cr 85Cr | -150.97Cr -131.47Cr -123.76Cr -111.46Cr -206.37Cr -13TCr -231.64Cr -1.44TCr -558.41Cr -5.91TCr -566.26Cr -554.5Cr -22TCr |
More financial data
* Estimated data
Employees
1,372
Sector
Pharmaceuticals
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 12/25/12 | 37.31 $ | -1.32% | 8,95,905 |
| 11/25/11 | 37.81 $ | -3.22% | 23,67,951 |
| 10/25/10 | 39.07 $ | -1.61% | 33,97,782 |
| 09/25/09 | 39.71 $ | -7.67% | 56,29,632 |
| 06/25/06 | 43.01 $ | +9.69% | 48,51,881 |
Delayed Quote Nasdaq, June 12, 2025 at 09:03 pm IST
More quotes
Sell
Buy
Mean consensus
BUY
Number of Analysts
26
Last Close Price
37.81USD
Average target price
89.96USD
Spread / Average Target
+137.92%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- SRPT Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition